A Multi-Center, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study Evaluating Efficacy and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis

Secukinumab efficacy and safety outcomes from a phase II subcutaneous dose-ranging study in the treatment of moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.11.849 ◽

2012 ◽

Vol 66 (4) ◽

pp. AB203

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Subcutaneous Dose ◽

Safety Outcomes ◽

Dose Ranging

Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

10.25251/skin.5.supp.15 ◽

2021 ◽

Vol 5 (1) ◽

pp. s15

Author(s):

RB Warren ◽

A Blauvelt ◽

J Bagel ◽

KA Papp ◽

P Yamauchi ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Active Comparator ◽

Severe Plaque Psoriasis ◽

Abstract not available.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

10.1111/bjd.19509 ◽

2020 ◽

Cited By ~ 1

Author(s):

A. Blauvelt ◽

C. Leonardi ◽

B. Elewski ◽

J.J. Crowley ◽

L.C. Guenther ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Double Blinded ◽

Blinded Trial

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

10.1111/bjd.12110 ◽

2013 ◽

Vol 168 (2) ◽

pp. 412-421 ◽

Cited By ~ 230

Author(s):

K.A. Papp ◽

R.G. Langley ◽

B. Sigurgeirsson ◽

M. Abe ◽

D.R. Baker ◽

...

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Dose Ranging

Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study

10.25251/skin.4.supp.82 ◽

2020 ◽

Vol 4 (6) ◽

pp. s82

Author(s):

K Reich ◽

K Papp ◽

A Blauvelt ◽

R Langley ◽

A Armstrong ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal

10.25251/skin.4.supp.83 ◽

2020 ◽

Vol 4 (6) ◽

pp. s83

Author(s):

K Gordon ◽

P Foley ◽

JG Krueger ◽

A Pinter ◽

K Reich ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate‐to‐severe plaque psoriasis – A randomised, double‐blinded, placebo‐controlled trial

10.1111/bjd.19747 ◽

2020 ◽

Author(s):

H. Hamm ◽

D. Wilsmann‐Theis ◽

A. Tsianakas ◽

T. Gambichler ◽

K. Taipale ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Young Patients ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Double Blinded ◽

Acid Esters

Faculty Opinions recommendation of Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962524.793471094 ◽

2013 ◽

Author(s):

Kamran Ghoreschi

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Dose Ranging

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

10.25251/skin.3.supp.34 ◽

2019 ◽

Vol 3 ◽

pp. S34

Author(s):

Andrew Blauvelt ◽

Kim A Papp ◽

Joseph F Merola ◽

Alice B Gottlieb ◽

Nancy Cross ◽

...

Keyword(s):

Plaque Psoriasis ◽

Extension Study ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial